![]() Just a month ago, Pfizer and BioNTech revealed that the American government had agreed to buy an additional 105 million vaccine doses, with the option to buy an additional 195 million. The need for COVID-19 vaccinations is still present in the meantime. However, success in those projects might eventually provide it with a more diverse stream of income. Years may pass before they receive regulatory approval (if at all), and the company won’t start making money from them until then. However, BNTX is now running 20 Phase 1 or 2 clinical trials, some of which use mRNA-based therapies to treat different malignancies. Nearly all of the company’s current sales are provided by Comirnaty. The warning, in this case, is that the biotech company’s margins may shift, particularly if demand for the Comirnaty vaccine declines dramatically. The impact of inflation might be somewhat offset by BioNTech while maintaining a profit margin of at least 50%. It has declared a net income of 12.9 billion euros on revenue of 23.3 billion euros for the previous 12 months, for a profit margin of 55%. Thanks to the COVID-19 vaccine that it co-developed with Pfizer, BioNTech has been reporting good sales and profit results. Individualized and commercially available mRNA-based therapeutics, chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies, and small compounds are all part of BioNTech’s portfolio of oncology products prospects. To create novel biopharmaceutical drugs quickly, the business integrates therapeutic drug platforms and computational discovery. BioNTech (NASDAQ: BNTX)BioNTech, an immunotherapy business, is developing cutting-edge treatments for critical illnesses, including cancer. ![]() From an investor’s standpoint, it could mean massive capital growth in the following years. The company’s stem cell research could be a breakthrough in slowing or eliminating these diseases as they are not yet curable. The company is now looking to move into commercialization as early as possible. This meant that the therapy had an effect on the disease process, not just the symptoms. However, substantial changes were seen across several cerebrospinal fluid biomarkers following NurOwn therapy, according to these data. The biggest impacts were shown in biomarkers linked to neuroinflammation and neuroprotection. ![]() In fact, studies from NurOwn’s Phase 3 ALS study produced impressive outcomes. ![]() BrainStorm Cell Therapeutics has developed a proprietary cellular technology platform called NurOwn to treat these diseases. It also performs preclinical trials on stem cell drugs against Huntington’s disease (HD), Parkinson’s disease (PD), and autism spectrum disorder. The company has medications in the pipeline to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and progressive multiple sclerosis, which has already been cleared for a phase III clinical trial. Although the company doesn’t have stem cell products, many are already in clinical development. BrainStorm Cell Therapeutics (NASDAQ: BCLI)Headquartered in New York, BrainStorm Cell Therapeutics looks to combat degenerative diseases using stem cells found in a patient’s bone marrow (autologous harvesting). Case studies & small human trial results are trumped by double-blind placebo controlled ones (Randomized Controlled Trials). Mouse results are trumped by human results. Best Stem Cell Stocks When interpreting scientific studies, let’s remember that cell culture results are trumped by mouse results. ![]()
0 Comments
Leave a Reply. |